Our results showed that pretreatment with candesartan, an AT1R blocker, reversed the resistance of hypoxic tumor cells to radiation exposure; this effect may correlate with the decreased HIF-1α expression due to Ang II signal-blocking in hypoxic tumor cells (Fig. 7b). Here, HIF1A is linked to neoplasm.